ASK THE EXPERTS: Advanced Neuroimaging of Glioblastoma
May 23rd 2024Nathalie Albert, MD, and Matthias Preusser, MD, explore the latest advancements in neuroimaging technologies and techniques, focusing on the use of amino acid tracers to enhance the diagnosis, treatment, and overall care of patients with glioblastoma.
My Treatment Approach: HER2+ Breast Cancer
May 17th 2024Tiffany A. Traina, MD; Vijayakrishna Gadi, MD, PhD, and Heather McArthur, MD, explore the current treatment landscape for HER2-positive metastatic breast cancer. They discuss standard of care therapies across lines, pivotal trial data, management of brain metastases, optimal sequencing strategies after, and emerging novel agents. Two patient cases help illustrate real-world decision-making.
Optimizing Patient Outcomes in High-Risk HR+, HER2- Early-Stage Breast Cancer
March 25th 2024Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, provide a comprehensive analysis of risk stratification in high-risk HR+/HER2- early-stage breast cancer, clinical approaches with high-risk breast cancer, recent trial data with CDK4/6 inhibitors, and strategies for managing toxicities for treatment continuity in the management of HR+/HER2- early-stage breast cancer, offering valuable insights to optimize patient care.
Year in Review: Updates in Treating Myelofibrosis
March 6th 2024Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, discuss the nuanced treatment landscape of myelofibrosis, exploring the latest advancements in JAK inhibitors, the importance of individualized care, and the potential of emerging combination therapies to enhance patient outcomes.
My Treatment Approach: Interpreting the Latest Data for Breast Cancer
December 13th 2023Expert medical oncologists Laura Spring, MD, and Manali Bhave, MD, discuss recent advances in the treatment of HER2-positive and HER2-low breast cancer, present hypothetical patient cases, and discuss their treatment approaches to illustrate how to incorporate recent data into practice.
My Treatment Approach: Evolving Treatment Strategies in Metastatic Melanoma
December 13th 2023A group of oncology experts discusses the adjuvant treatment of melanoma, providing expert insights into the management of immunotherapy-related endocrine and cardiac toxicities, with a case discussion to emphasize these important topics.
FGFR Inhibitors: Best Practices for Managing Treatment and Treatment-Related Adverse Events
December 13th 2023Patient and provider perspectives are shared regarding available treatments, as well as how to manage treatment-related adverse events that can effect the quality of life for a patient diagnosed with cholangiocarcinoma.
This page is funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this page is not medical advice and does not replace independent medical judgment.
Year in Review: Updates in Immunotherapy-Based Treatment Approaches for NSCLC
December 13th 2023Edgardo Santos, MD, FACP, FCCP, clinical affiliate associate professor, Florida Atlantic University; Vice-President, Florida Society of Clinical Oncology, discusses key advancements in immunotherapy-based treatment approaches for NSCLC in 2023.
Advances in the Treatment and Management of Myelodysplastic Syndrome (MDS): The Role of Oral HMAs
December 13th 2023Join Dr. Guillermo Garcia-Manero in this OncLive Insights program as he delves into the latest advancements in the treatment of myelodysplastic syndrome (MDS), with a specific focus on the emerging role of oral hypomethylating agents (HMAs).
This page is funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this page is not medical advice and does not replace independent medical judgment.
Exploring Hepatotoxicity and Treatment Outcomes of Targeting KRAS G12C Mutations in mNSCLC
November 29th 2023Expert oncologists reflect on the evolving treatment paradigm for KRAS-mutated metastatic NSCLC with insight into data from ESMO 2023 and surrounding meetings, discussing targeted therapies and future perspectives in clinical practice.
Optimizing Therapy for Endometrial Cancer: Recent Data Highlights
October 30th 2023Discover the latest advancements and challenges in the treatment of endometrial cancer, from therapeutic breakthroughs to the importance of diverse clinical trial enrollment, presented by leading experts in gynecologic oncology.